Christi Shaw - 12 Jan 2026 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Executive Chairperson, Director
Signature
By: /s/ Samantha Eldredge, as Attorney-in-Fact
Issuer symbol
KYTX
Transactions as of
12 Jan 2026
Net transactions value
$0
Form type
4
Filing time
14 Jan 2026, 17:00:10 UTC
Previous filing
06 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shaw Christi Executive Chairperson, Director C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE By: /s/ Samantha Eldredge, as Attorney-in-Fact 14 Jan 2026 0001702473

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Award $0 +30,000 +180% $0.000000 46,634 12 Jan 2026 Direct F1
transaction KYTX Common Stock Award $0 +24,301 +52% $0.000000 70,935 12 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Stock Option (right to buy) Award $0 +185,000 $0.000000 185,000 12 Jan 2026 Common Stock 185,000 $8.23 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit award of common stock, 1/4th of the shares subject to which shall vest on January 12, 2027, and 1/4th of the shares subject to the restricted stock unit award shall vest following each one-year period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2 Represents a performance restricted stock unit award of common stock, which will vest upon the Issuer's common stock achieving certain specified prices per share.
F3 1/4th of the shares subject to the option shall vest on January 12, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.